BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm

BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines declined.CFO Jens Holstein said the drop for the shot was seasonal, and the company expected 90% of its revenue coming later in the year.Holstein noted that BioNTech has billions in cash on hand to drive the company's efforts into treatments for cancer. American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine make ...